BioSpace News Archive

Stericycle, Inc., a leading provider of medical waste management, secure information destruction and patient engagement solutions, announced chief executive officer Cindy J. Miller has been named to the Forbes 50 Over 50 list.

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Lytham Partners Summer 2021 Investor Conference.

IceCure Medical Ltd. (TASE: ICCM) (“IceCure” or the “Company”), today announced that it has entered into an exclusive distribution agreement with KTRFIOS IMPORTACAO E EXPORTACAO LTDA (the “Distributor”) to sell the Company’s ProSense™ Cryoablation System in Brazil,

MEI Pharma, Inc. (NASDAQ: MEIP), and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), today announced the dosing of the first patient with relapsed or refractory marginal zone lymphoma enrolled in the recently added second arm of the global Phase 2 TIDAL study of zandelisib,

Ardelyx, Inc. (Nasdaq: ARDX), today announced two presentations highlighting new tenapanor data at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Virtual Congress 2021

Crestone, Inc. today announced the first patient has been enrolled in a Phase 2 clinical trial of CRS3123 for the treatment of Clostridioides difficile infection (CDI).

Melior Pharmaceuticals (Melior) announced that it has signed a “letter of intent” with Adhera Therapeutics, Inc . (OTCPK: ATRX; Adhera) for the acquisition of Melior’s Parkinson’s disease (PD) candidate, MLR-1019 (armesocarb).

Experienced foundation relations professional will spearhead fundraising efforts and help the organization provide individualized therapies to the ultra-rare disease community n-Lorem Foundation continues to grow its team with second new hire this quarter

Data suggest short-term treatment with vorasidenib and TIBSOVO reduces tumor cell proliferation, alters epigenetic state, and promotes expression of genes associated with cellular differentiation BOSTON , J

Kiromic BioPharma, Inc. (Nasdaq: KRBP) — Expansion of in-house cGMP manufacturing facility to provide support to the Company’s clinical trials. Therapeutic doses expected to be ready for first in-human dosing in 3Q-2021. — Mr. Ignacio Núñez, a 20-year industry veteran in global operations and manufacturing, is joining the Kiromic team to take the company to the next level and to scale up cGMP manufacturing capabilities